• 
• 
• 
• 
  • Ogłoszenia
  • Plan wydawniczy
  • Regulamin ogłaszania prac
  • Zasady recenzowania i recenzenci
• 
• 
• 
• 

Wydanie specjalne czerwiec 2017
str. 24 - 26

Analiza wyników leczenia chorych według schematu proaktywnego w ramach programu lekowego „Leczenie neowaskularnej (wysiękowej) postaci zwyrodnienia plamki związanego z wiekiem” w pierwszym roku jego trwania w Klinice Okulistyki Ogólnej Uniwers

Analysis of Results of Proactive Regimen Treatment in “The neovascular Age-related Macular Degeneration” in Drug Prescription Program in the First Year of its Duration in the Department of General Ophthalmology in Lublin

Anna Matysik-Woźniak ¹ , Małgorzata Ozimek ¹ , Edyta Koman ¹ , Dominika Nowakowska ¹ , Robert Rejdak ^1,2

¹ Klinika Okulistyki Ogólnej Uniwersytetu Medycznego w Lublinie
Kierownik: prof. dr hab. n. med. Robert Rejdak
² Zakład Farmakologii Doświadczalnej Instytutu Medycyny Doświadczalnej i Klinicznej Polskiej Akademii Nauk
Kierownik: prof. dr hab. n. med. Paweł Grieb

Summary: Age-related macular degeneration is a leading cause of vision impairment in individuals over the age of 50 in the developed countries. Nowadays anti-vascular endothelial growth factor drugs are the gold standard of this disease treatment. In clinical practice there are three treatment regimens: proactive, as needed and „treat and extend”.
“The neovascular Age-related Macular Degeneration Drug Prescription Program” is realized in Poland since October 2015. The program is conducted in 136 centers, contracted with “The neovascular Age-related Macular Degeneration Drug Prescription Program”.
Purpose: Assessment of the efficacy of proactive regimen based on the results obtained in the first year course of National Health Fund Drug Prescription Program “Treatment of neovascular (exudative) form of age-related macular degeneration” in the Department of General Ophthalmology of Medical University of Lublin.
Material and methods: Treatment effects were assessed in 17 patients (18 eyes) with treatment-naïve neovascular age-related macular degeneration. Patients began treatment at the turn of the year 2015/2016 and receive intravitreal injections of aflibercept (2.0 mg) in proactive regimen. Parameters evaluated during and at the end of the treatment: best corrected visual acuity on Snellen charts, central retinal thickness using optical coherent tomography and adverse events.
Results: After 6 doses of aflibercept mean best corrected visual acuity was 0.40 and mean visual acuity gain compared with baseline was 0.08 (p = 0.018). At the end of the treatment mean decrease in central retinal thickness was 45.0 µm and the mean central retinal thickness was 252.0 µm. No serious adverse events were observed.
Conclusion: The analysis confirmed the efficacy and safety of proactive regimen in the treatment of neovascular age-related macular degeneration.

Słowa kluczowe: zwyrodnienie plamki związane z wiekiem (AMD), inhibitory czynnika wzrostu śródbłonka naczyniowego (leki anty-VEGF), program lekowy AMD, schemat proaktywny.

Keywords: age-related macular degeneration (AMD), anti vascular endothelial growth factor drugs (anti-VEGF drugs), nAMD Drug Prescription Program, proactive regimen.

powrót